GleamWall
中文EN

IDXX IDEXX LABORATORIES INC /DE

In Vitro & In Vivo Diagnostic Substances · Nasdaq · SEC CIK 874716 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY11.9%
TTM net income YoY15.1%
TTM EPS YoY17.7%
Revenue 3-yr CAGR9.1%
Net income 3-yr CAGR12.8%

Margins

Gross margin62.7%
Operating margin32.3%
Net margin25.4%
FCF margin28.0%
EBITDA margin35.7%

Returns

ROE68.9%
ROA33.3%
ROIC (approx.)61.4%
Asset turnover1.31x

Leverage & solvency

Liabilities / assets49.6%
Debt / equity0.20x
Current ratio1.19x
Interest coverage43.54x

Cash quality & payout

Operating cash flow / net income1.20x
Accruals ratio-6.7%
Payout ratio—
Capex / revenue2.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$4.30B$3.90B
Cost of revenue$1.64B$1.52B
Gross profit$2.66B$2.38B
R&D expense$251.21M$219.79M
SG&A expense$404.79M$442.29M
Operating income$1.36B$1.13B
Interest expense$38.85M$31.20M
Pretax income$1.32B$1.11B
Income tax$264.73M$221.96M
Net income$1.06B$887.87M
EBITDA$1.51B$1.26B
EPS (basic)13.1710.77
EPS (diluted)13.0810.67
Weighted avg. shares (diluted)81.03M83.25M
Banking
Provision for credit losses$8.43M$6.87M
Balance sheet
Cash & equivalents$180.07M$288.27M
Receivables$552.38M$473.57M
Inventory$377.76M$381.88M
Current assets$1.41B$1.40B
PP&E, net$747.38M$713.12M
Goodwill$414.00M$405.10M
Intangibles$109.84M$111.68M
Total assets$3.35B$3.29B
Current liabilities$1.15B$1.07B
Short-term debt$75.00M$167.79M
Long-term debt$374.84M$449.79M
Total debt$449.84M$617.57M
Total liabilities$1.75B$1.70B
Shareholders' equity$1.61B$1.60B
Net debt$269.77M$329.31M
Shares outstanding79.71M81.60M
Cash flow statement
Operating cash flow$1.18B$929.00M
Capital expenditure$124.68M$120.92M
Free cash flow$1.06B$808.08M
Investing cash flow-$136.24M-$207.06M
Financing cash flow-$1.16B-$878.07M
Depreciation & amortization$145.18M$129.94M
Stock-based compensation$60.01M$60.30M
Share buybacks$1.22B$837.03M

Free plan shows the latest 2 periods; Pro shows all 18 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.